Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination therapy consisting of donepezil, an acetylcholinesterase inhibitor, and Woohwangchungsimwon, a traditional herbal medicine. Donepezil works by selectively and reversibly inhibiting the acetylcholinesterase enzyme in the central nervous system, thereby increasing acetylcholine levels and improving cognitive and behavioral symptoms associated with Alzheimer's disease. Woohwangchungsimwon is frequently prescribed for neuropsychiatric disorders in traditional Korean medicine and has been reported to have beneficial effects on behavioral and psychological symptoms of dementia. The combination is being studied for its potential to alleviate these symptoms in patients with probable Alzheimer's disease[1][2][4]. A randomized controlled trial is underway to evaluate efficacy and safety over 24 weeks, focusing on outcomes such as neuropsychiatric inventory scores, cognitive function, dementia severity, quality of life, depression, anxiety, insomnia, adverse reactions, vital signs monitoring, and laboratory tests[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on donepezil + woohwangchungsimwon.